Fast-Growing Pharma Company Prepares to Launch OTC Nasal Spray

Source:   ()
A San Diego-based pharmaceutical company that focuses on over-the-counter medications reported strong Q1/17 results and expects to begin marketing a nasal spray by the end of the year. read more >

Phase 3 Trial for Inovio's VGX-3100 in Cervical Dysplasia Gets FDA Go-Ahead

Source:   ()
Now that the FDA has lifted its clinical hold on Phase 3 study of Inovio Pharmaceutical's immunotherapy for cervical dysplasia, three analysts are making note of what the progress means for both the company and investors. read more >

RXi Pharmaceuticals Expands Collaboration with Norwegian Cancer Firm; Gears Up for 2017 Milestones

Source:   ()
The potential of RXi Pharmaceuticals' sd-rxRNA technology in the development of cancer immunotherapies has resulted in an extension of its research collaboration with Oslo-based PCI Biotech and captured the attention of two analysts. read more >

HIV Vaccine Clinical Study Results in High Immune Response Rates in Healthy Subjects

Source:   ()
A clinical study of an HIV vaccine in healthy subjects that found a nearly 100% immune response rate was hailed by a pair of industry analysts. read more >

Neuromonitoring Company Founded by Former NFL Quarterback Set to Go Public

Source:   ()
Assure Holdings, an intraoperative neuromonitoring company founded by former NFL quarterback Preston Parsons, will begin trading on the TSX Venture Exchange on May 29, under the trading symbol IOM. read more >

What Is Chen Buying? Gold, Cobalt, Phosphate and Biotech. . .

Contributed Opinion
Source:   ()
With the market in flux, Chen Lin of the popular newsletter What Is Chen Buying?, What Is Chen Selling? is hedging his bets with investments in a variety of companies in different sectors. read more >

Small-Caps Rushing to Fill the NASH Treatment Pipeline

Source:   ()
NASH is an epidemic in the U.S., with more than 100 million people believed to be affected. Yet no FDA-approved treatments are available, with the exception of liver transplantation for end-stage disease. In part two of his interview with The Life Sciences Report, Ed Arce, managing director in equity research and senior analyst covering companies in the biopharmaceuticals and specialty pharmaceuticals sectors for H.C. Wainwright, and organizer of the recent inaugural NASH Investor Conference, says that small companies are rushing to fill the pipeline, with numerous compounds in trials. read more >
Expert Investing Ideas

"SNSS' SNS-062 Phase Ib/II is expected to begin in H1/17."

–Maxim Jacobs, Edison Investment Research


NASDAQ Biotech ARCA Pharmaceutical

Innovative Company Focused on Women's Health Completes Record-Breaking Quarter

Source:   ()
Viveve Medical's Q1/17 results beat expectations, an accomplishment that was welcomed by several industry analysts. read more >

Big Pharma Sets Its Sights on NASH Epidemic

Source:   ()
Up to one-third of Americans may have conditions that lead to NASH, yet the disease is far from a household name. Closely linked with obesity, the disease does not become symptomatic until very late stage. Ed Arce, managing director in equity research and a senior analyst covering companies in the biopharmaceuticals and specialty pharmaceuticals sectors for H.C. Wainwright, organized the recent inaugural NASH Investor Conference. In part one of his interview with The Life Sciences Report, Arce discusses the disease, its market potential and how companies large and small are trying to fix the current dearth of treatments. read more >

Sunesis Pharmaceuticals Shifts Focus to Leukemia Drug

Source:   ()
In light of a decision to pull its application for approval of vosaroxin in the European Union, Sunesis Pharmaceuticals has designated its BTK inhibitor program targeting chronic lymphocytic leukemia as its new lead program. read more >
Management Q&A: View from the Top

Inovio Moves Forward on Brain Cancer and Cancers Caused by HPV; Zika and Ebola Vaccines Also Advance

Managment Q&A: View from the Top
Source:   ()
Inovio Pharmaceuticals' pipeline of vaccine and immunotherapeutic products is advancing steadily through the phases of development, with a host of milestones anticipated in 2017, including the start of a Phase 3 trial in cervical dysplasia and the initiation of trials with partners in brain cancer and cancers caused by human papillomavirus. In this interview with The Life Sciences Report, Inovio President and CEO, Dr. J. Joseph Kim, walks investors through the promising possibilities, and also provides updates on its vaccines for the Zika, MERS and Ebola viruses. read more >